# Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

> **NCT00538694** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Pneumonia, Bacterial

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00538694
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10-31
- **Primary completion:** 2001-09-30
- **Final completion:** 2001-09-30
- **Target enrollment:** — (—)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538694, "Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00538694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*